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Objective:A prospective, international registry study was initiated to provide contemporary comparative data on
short-term clinical outcomes after aortic valve-sparing and aortic valve-replacing root operations in patients with
Marfan syndrome. The purpose of this initial report is to describe the study design and to compare early outcomes
in the first 151 enrolled patients.
Methods:We assessed 30-day outcomes in 151 patients who met strict Ghent diagnostic criteria for Marfan syn-
drome and underwent aortic root replacement with either valve-replacing (n ¼ 46) or valve-sparing techniques
(n ¼ 105) at one of 18 participating centers. In the valve replacement group, a mechanical composite valve graft
was used in 39 (85%) patients and a bioprosthetic valve in 7 (15%). In the valve-sparing group, David V pro-
cedures were performed in 57 (54%) patients, David I in 38 (36%), David IV in 8 (8%), Florida sleeve in 1
(1%), and Yacoub remodeling in 1 (1%).
Results:No in-hospital or 30-day deaths occurred. Despite longer crossclamp and cardiopulmonary bypass times
in the valve-sparing group, there were no significant between-group differences in postoperative complications.
Thirty-day valve-related complications occurred in 2 (4%) patients undergoing valve replacement and in 3 (3%)
undergoing valve-sparing procedures (P ¼ .6).
Conclusions: The analysis of early outcomes revealed that valve-sparing techniqueswere themost common approach
to root replacement in patients with Marfan syndrome in these centers. The complexity of valve-sparing root replace-
ment did not translate into any demonstrable adverse early outcomes. Subsequent analysis will compare the 3-year
durability of these two surgical approaches.
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doi:10.1016/j.jtcvs.2009.03.0231124 The Journal of Thoracic and Cardiovascular SuPatients with Marfan syndrome (MFS) have an inborn con-
nective tissue defect that involves multiple organ systems.1
Aortic root dilatation is the predominant cardiovascular le-
sion, affecting about 64% of children and 80% of adults
with MFS. If untreated, it can lead to life-threatening aortic
dissection, rupture, or both.2-4
Replacing the aortic valve and root with a composite valve
graft has been the mainstay of surgical treatment of aortic root
abnormalities since the technique was introduced by Bentall
and de Bono5 in the 1960s.6-9 Techniques for aortic valve-
sparing (AVS) root replacement were subsequently intro-
duced by Yacoub in 1979 (remodeling) and David in 1988
(reimplantation).10,11 Concern about potential deterioration
of the preserved aortic valve leaflets has created controversy
regarding the durability of AVS reconstructions in patients
with MFS.12-14 Despite this concern, and although AVS
root replacement operations are more technically demanding
than aortic valve-replacing (AVR) procedures, AVS ap-
proaches have been enthusiastically accepted by many sur-
geons and MFS patients because anticoagulation is not
necessary. A prospective, international registry study—Aortic
Valve Operative Outcomes in Marfan Patients—was initiated
to provide contemporary comparative data on short-termrgery c May 2009
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DAbbreviations and Acronyms
AVR ¼ aortic valve-replacing
AVS ¼ aortic valve-sparing
DCC ¼ Data Coordination Center
MFS ¼ Marfan syndrome
clinical outcomes after AVS and AVR root operations in
patients with MFS. The purpose of this initial report is to
describe the registry study design and to compare the early
outcomes in the first 151 enrolled patients.
PATIENTS AND METHODS
Overall Study Design, Study Organization, and
Patient Recruitment Protocol
This multicenter study is designed to prospectively evaluate clinical out-
comes after aortic root replacement using either AVR or AVS techniques in
patientswithMFS.There is no attempt to assign the type of repair that patients
receive; the choice of operation is based onclinical factors andon surgeonand
patient preference. The primary end point for the study is the composite inci-
dence of all valve-related complications. Based on an estimated event rate of
20%, the study is designed with a target sample size of 250, which provides
80% power (a ¼ .05) to detect a 1.85-fold increase in the relative risk of
valve-related complications between the AVR and AVS groups.
The Data Coordination Center (DCC), Marfan Diagnostic Core, Imaging
Core, Surgical Core, andGenetic Repository coordinate the study. The DCC
developed the study protocol and monitors its implementation in terms of
data collection and management, as well as providing coordination and
administrative support to all participating institutions. The study protocol
has been approved by the institutional review board or ethics committee at
each participating institution. TheMarfan Diagnostic Core reviews each pa-
tient’s eligibility for enrollment by verifying the clinical diagnosis of MFS.
Imaging studies are collected and analyzed by the Imaging Core. The Surgi-
cal Coremanages the collection of standardized surgical data. Blood and aor-
tic tissue samples are obtained and stored at the study’s Genetic Repository
for future analysis and will be available to interested investigators.
Patients with a confirmed or tentative diagnosis of MFS who need aortic
root surgery are consecutively approached for participation in the study,
including patients having emergent or urgent surgery. All recruited patients
sign a consent form. To participate, patients must meet strict Ghent criteria,1
need aortic root surgery, and be available for follow-up.
Data Collection and Definitions
The study sites prospectively collect clinical data on preoperative status,
operation type and details, and postoperative and follow-up status by using
data collection forms developed by the DCC and approved by the Profes-
sional Advisory Board of the National Marfan Foundation. Follow-up infor-
mation is obtained 6, 12, 24, and 36 months after surgery. Whenever
available, echocardiograms performed before surgery, at discharge, and dur-
ing follow-up are collected and reviewed by the Imaging Core. Before the
operation and 1 year afterward, patients complete the SF36v2 health-related
quality of life questionnaire (QualityMetric, Inc, Lincoln, RI). After each op-
eration, the surgeon completes a questionnaire on the timing of the decision
betweenAVR andAVS techniques and the reasons for the surgeon’s choice.
All study sites enter their data into a secure on-line data collection and
study management system provided and maintained by Velos, Inc
(Freemont, Calif). Initial data validation is performed by built-in data type
and range/limit checks. Mandatory data entry for selected fields prevents
the omission of data for essential variables. During quarterly data reviews,
the DCC performs logic checks, identifies all missing data in the nonman-The Journal of Thoracic and Cdatory fields, and requests clarification of discrepancies and submission
of missing data from study sites. Finally, the DCC performs annual visits
to selected sites to review study documentation, assure protocol compliance,
and check on-line data entries against source documentation for approxi-
mately 15% of enrolled patients.
In the present analysis, operations were categorized as AVS or AVR
according to the initial procedure performed. The AVS procedures were de-
scribed according to the classification system suggested byMiller12 in 2003.
Emergent operations were defined asmandatedwithin 24 hours after presen-
tation because of the patient’s medical condition, urgent operations as man-
dated within 7 days after presentation, and elective operations as performed
at the convenience of both the surgeon and the patient. Duration of surgery
was defined as the interval between skin incision and skin closure.
The definitions of valve-related morbidity and mortality were based on
the recommendations in the 1996 guidelines written by Edmunds and col-
leagues.15 Valve-related complications were defined as structural valvular
deterioration, nonstructural valve dysfunction, valve thrombosis, embolism
(ie, neurologic events and peripheral embolic events), operated valvular
endocarditis, or bleeding. Bleeding events were considered to be valve-
related complications if they occurred after discharge and caused death,
hospitalization, or permanent injury or if they necessitated transfusion,
regardless of whether the patient was taking anticoagulant or antiplatelet
drugs; early postoperative bleeding events, such as mediastinal hemorrhage
necessitating re-exploration, were recorded separately and were not catego-
rized as valve-related complications. Cardiac complications encompassed
myocardial infarction, atrial or ventricular arrhythmia requiring treatment,
pericardial effusion necessitating drainage, and cardiac failure necessitating
inotropic support for more than 48 hours, intra-aortic balloon counterpulsa-
tion, or mechanical ventricular assistance. Pulmonary complications
included the need for more than 48 hours of ventilatory support, respiratory
failure necessitating reintubation, adult respiratory distress syndrome,
atelectasis necessitating bronchoscopy, chylothorax, prolonged air leak,
pneumonia, and pleural effusion or pneumothorax necessitating an evacua-
tion procedure. Acute renal dysfunction was defined as a serum creatinine
level that was more than double the baseline level.
Patients and Operations
Two hundred fourteen consecutive patients who required aortic root
replacement and were suspected to haveMFSwere approached for potential
enrollment in the study at 18 tertiary institutions in North and South Amer-
ica and Europe during the period of March 1, 2005, to January 31, 2008. Of
these patients, 6 declined to participate, 23 did not meet Ghent criteria, and
22 had not yet completed the diagnostic screening process. Thus, 163
patients met the screening criteria and were enrolled; this group represents
65% of the 250 patients needed to complete study enrollment. Twelve of the
patients had been enrolled recently and did not yet have complete 30-day
data; these patients were excluded, leaving 151 patients in the analysis of
early outcomes.
Table 1 provides demographic and clinical information obtained at pre-
sentation, by type of operation. The types of aortic root replacement proce-
dures and the details of the operations are provided in Tables 2 and 3,
respectively. Aortic root replacement was performed through a standard,
full median sternotomy in 145 (96%) patients. Of the 6 remaining patients,
4 had transverse sternotomies, and 2 had upper hemisternotomies. One hun-
dred five (70%) patients underwent an AVS procedure. The David V tech-
nique, used in 57 (54%) AVS patients, was the most common procedure.
All but one of the AVS patients had a reimplantation procedure; one Yacoub
remodeling operation was performed. TwoAVS patients required intraoper-
ative conversion to AVR; they were included in the AVS group for analysis
because AVS was the initial procedure performed. Either direct cusp repair
or shortening of the cusp freemargin was performed in 22 (21%) patients; of
these patients, 15 (68%) had both cusp repair and free margin shortening, 5
(23%) had only free margin shortening, and 2 (9%) had only direct cusp re-
pair. Forty-six (30%) patients underwent AVR procedures; most of theseardiovascular Surgery c Volume 137, Number 5 1125
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DTABLE 1. Presenting characteristics of 151 patients with MFS undergoing aortic root replacement
Variable Total (n ¼ 151) AVR (n ¼ 46) AVS (n ¼ 105) P value
Age, y, mean  SD (range) 33  13 (4–69) 39  13 (16–69) 31  12 (4–64) <.01
Male sex 102 (68%) 34 (74%) 68 (65%) .3
Hypertension 37 (25%) 13 (28%) 24 (23%) .5
Hypercholesterolemia 6 (4%) 2 (4%) 4 (4%) 1.0*
Diabetes 1 (1%) 0 1 (1%) 1.0*
Current smoker 17 (12%) 5 (11%) 12 (12%) .8
Former smoker 42 (29%) 11 (25%) 31 (30%)
Recent cerebrovascular accident 4 (3%) 3 (7%) 1 (1%) .08*
Chronic obstructive lung disease 1 (1%) 0 1 (1%) 1.0*
Pneumonia 1 (1%) 1 (2%) 0 .3*
Pulmonary hypertension 2 (1%) 0 2 (2%) 1.0*
Coronary artery disease 1 (1%) 0 1 (1%) 1.0*
Myocardial infarction within 24 h 1 (1%) 0 1 (1%) 1.0*
Cardiomyopathy 2 (1%) 1 (2%) 1 (1%) .5*
Mitral valve disease 35 (23%) 10 (22%) 25 (24%) .8
Endocarditis 0 0 0 —
Coagulopathy 4 (3%) 2 (4%) 2 (2%) .6*
NYHA class
I 109 (74%) 32 (73%) 77 (74%) .7
II 30 (20%) 8 (18%) 22 (21%)
III 6 (4%) 3 (7%) 3 (3%)
IV 3 (2%) 1 (2%) 2 (2%)
Left ventricular ejection fraction,%,
median (IQR) (No. of observations)
60 (55–65) 60 (55–65) 60 (55–65) .6y
(139) (45) (94)
Sinus rhythm 147 (97%) 45 (98%) 102 (97%) 1.0*
Aortic regurgitation (No. of observations) (144) (45) (99)
None/trivial 95 (66%) 24 (53%) 71 (72%) <.01
Mild 26 (18%) 6 (13%) 20 (20%)
Moderate 9 (6%) 6 (13%) 3 (3%)
Severe 14 (10%) 9 (20%) 5 (5%)
Aortic dimensions, mm
Annulus, mean  SD (No. of observations) 26  3 (114) 27  3 (39) 26  3 (75) .1
Sinuses of Valsalva, median (IQR)
(No. of observations)
50 (47–54) 52 (50–56) 50 (47–52) .2y
(124) (41) (83)
Sinotubular junction, mean  SD
(No. of observations)
38  8 (108) 39  10 (37) 38  7 (71) .4
Ascending aortic dissection 12 (8%) 6 (13%) 6 (6%) .2
Acute dissection 6 (4%) 3 (7%) 3 (3%) .4*
Chronic dissection 6 (4%) 3 (7%) 3 (3%) .4*
Aortic rupture 0 0 0 —
Previous CV surgery 10 (7%) 6 (13%) 4 (4%) .07*
No. of previous CV operations
One 8 (5%) 5 (11%) 3 (3%) .1*
Two 1 (1%) 0 1 (1%) 1.0*
Three 1 (1%) 1 (2%) 0 .3*
Type of previous CV surgery
Isolated aortic valve replacement 1 (1%) 1 (2%) 0 .3*
Homograft root 1 (1%) 1 (2%) 0 .3*
Mitral valve repair/replacement 2 (1%) 0 2 (2%) 1.0*
Aortic aneurysm repair
Ascending aorta 1 (1%) 1 (2%) 0 .3*
Descending thoracic aorta 1 (1%) 0 1 (1%) 1.0*
Abdominal aorta 1 (1%) 1 (2%) 0 .3*1126 The Journal of Thoracic and Cardiovascular Surgery c May 2009
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DTABLE 1. Continued
Variable Total (n ¼ 151) AVR (n ¼ 46) AVS (n ¼ 105) P value
Aortic dissection repair
Stanford A 3 (2%) 3 (7%) 0 .03*
Stanford B 2 (1%) 0 2 (2%) 1.0*
Other CV operations 6 (4%) 3 (7%) 3 (3%) .4*
Creatinine, mg/dL, mean  SD 0.9  0.2 1.0  0.2 0.9  0.2 <.01
Renal failure 1 (1%) 1 (2%) 0 .3*
Data are presented as number and percentage of patients unless otherwise specified.MFS,Marfan syndrome; AVR, aortic valve-replacing; AVS, aortic valve-sparing; SD, standard
deviation; NYHA, New York Heart Association; IQR, interquartile range; CV, cardiovascular. *Fisher’s exact test. yKolmogorov–Smirnov 2-sample test.patients (n¼ 39; 85%) received a composite valve graft incorporating a me-
chanical prosthesis.
Follow-up Data
Thirty-day and hospital outcome data were complete for all 151 patients.
Discharge echocardiograms were obtained for 144 (95%) patients. In 100
(69%) of the echocardiograms, the Imaging Core was able to assess aortic
valve function. Two echocardiograms did not provide adequate visualiza-
tion of the aortic valve. For the remaining 42 patients, Imaging Core analysis
was not possible because of logistical or data formatting problems; for these
patients, data were abstracted from the study-site echocardiogram reports.
Statistical Analysis
Given the distribution of AVR and AVS procedures in the first 151 pa-
tients, this analysis had 80% power to detect a relative risk of 2.15 (a¼ .05)
for valve-related complications, theprimary study endpoint. Normally distrib-
uted continuous variables were presented as mean  SD and compared
between groups by Student t tests. Nonnormally distributed continuous vari-
ables were presented as medians and interquartile ranges; the Kolmogorov–
Smirnov test was used for between-group comparisons. Categorical variables
were presented as frequencies and percentages; c2 or Fisher’s exact tests were
used for between-group comparisons, as appropriate.
To control for confounding factors, we performed stepwise multivariable
logistic regression analysis to determine whether type of operative proce-
dure was an independent predictor of early valve-related complications.
Univariate predictors with P values less than .2 were included in the regres-
sion model. Data on 140 patients were complete and therefore included in
the model. The DCC performed the statistical analyses with SPSS 16.0 sta-
tistical software (SPSS Inc, Chicago, Ill).
TABLE 2. Types of aortic root replacement operations in 151 patients
with MFS
Type of root replacement No. (n ¼ 151)
Valve-replacing 46 (30%)
Mechanical composite valve graft 39
Stented bioprosthetic composite valve graft 5
Homograft 1
Stentless porcine root 1
Valve-sparing 105 (70%)
Reimplantation 104
David V 57
David I 38
David IV 8
Florida sleeve 1
Remodeling 1
MFS, Marfan syndrome.The Journal of Thoracic and CaRESULTS
Overall Outcomes
No 30-day or in-hospital deaths occurred in either group.
There were no strokes and no reoperations on the aortic
valve. One patient undergoing AVS surgery required reoper-
ation to correct coronary artery kinking after a Florida sleeve
procedure. In 2 patients, heart block developed that necessi-
tated placement of a permanent pacemaker. The overall inci-
dence of valve-related complications at 30 days was 3%
(Table 4); the complications included 1 bleeding event, 1 re-
versible ischemic neurologic deficit, and 3 cases of intrao-
perative nonstructural valve dysfunction. The valve-related
bleeding event was a bloody pericardial effusion that oc-
curred after discharge on the 15th postoperative day and re-
quired pericardial drainage. All other early bleeding events
occurred before discharge and did not meet the criteria
for classification as valve-related complications. Thirteen
(9%) patients required re-exploration for bleeding; a bleed-
ing site involving the root repair (eg, at the annulus or a cor-
onary anastomosis) was identified in 3 of these patients. Five
patients with bleeding did not require mediastinal re-explo-
ration. Of those, 3 had bloody pericardial effusions with
cardiac tamponade (2 were drained, and 1 was treated non-
operatively), 1 had early postoperative bleeding that did
not require reoperation, and 1 had a right hemothorax that re-
quired drainage. Two patients having AVS surgery had em-
bolic complications: 1 patient had a reversible ischemic
neurologic deficit 7 days after surgery, and 1 had a pulmo-
nary embolus on postoperative day 12; the latter was not
considered valve-related. Three patients had nonstructural
valve dysfunction resulting in aortic regurgitation that was
detected intraoperatively and treated during the same opera-
tion. Two of these patients had unsuccessful attempts at
AVS root replacement (1 Yacoub remodeling and 1 David
I reimplantation) and required conversion to AVR. The third
patient with nonstructural valve dysfunction had substantial
aortic regurgitation immediately after a cryopreserved ho-
mograft root was implanted; the homograft valve leaflets
were excised and replaced with a stented bioprosthetic
valve. There were no early cases of structural valve deterio-
ration, valve thrombosis, or endocarditis. Of the 144 patients
with postoperative echocardiograms, aortic valve functionrdiovascular Surgery c Volume 137, Number 5 1127
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DTABLE 3. Operative details for 151 aortic root replacements in patients with MFS
Variable Total (n ¼ 151) AVR (n ¼ 46) AVS (n ¼ 105) P value
Urgency of surgery
Elective 134 (89%) 35 (76%) 99 (94%) <.01
Urgent 6 (4%) 3 (7%) 3 (3%)
Emergent 11 (7%) 8 (17%) 3 (3%)
Perfusion technique
Cardiopulmonary bypass alone 109 (72%) 33 (72%) 76 (72%) .9
Circulatory arrest 42 (28%) 13 (28%) 29 (28%) .9
HCA without perfusion adjuncts 13 (9%) 3 (7%) 10 (10%) .8*
HCA with ACP 10 (7%) 3 (7%) 7 (7%) 1.0*
HCA with RCP 16 (11%) 6 (13%) 10 (10%) .5
HCA with ACPþRCP 3 (2%) 1 (2%) 2 (2%) 1.0*
Cardiopulmonary bypass time, min, median (IQR) 177 (142–252) 148 (107–199) 191 (157–271) <.01y
Aortic crossclamp time, min, median (IQR) 140 (108–208) 114 (76–166) 150 (120–225) <.01y
Concomitant procedures
Hemiarch 31 (21%) 10 (22%) 21 (20%) .8
Full arch (without elephant trunk) 4 (3%) 0 4 (4%) .3*
Elephant trunk arch 4 (3%) 3 (7%) 1 (1%) .08*
Mitral valve replacement 2 (1%) 1 (2%) 1 (1%) .5*
Mitral valve repair 10 (7%) 2 (4%) 8 (8%) .5*
Coronary artery bypass 6 (4%) 3 (7%) 3 (3%) .4*
Duration of surgery, min, median (IQR) 335 (259–395) 293 (230–367) 340 (274–420) .02y
Data are presented as number and percentage of patients unless otherwise specified.MFS,Marfan syndrome; AVR, aortic valve-replacing; AVS, aortic valve-sparing;HCA, hypothermic
circulatory arrest; ACP, antegrade cerebral perfusion; RCP, retrograde cerebral perfusion; IQR, interquartile range. *Fisher’s exact test; yKolmogorov–Smirnov 2-sample test.could be assessed in 142; 140 patients had no or trivial aortic
valve regurgitation, and 2 had mild regurgitation.
Comparison of AVR and AVS Groups
Compared with patients who underwent AVR root re-
placement, those who underwent AVS procedures were sig-
nificantly younger and were less likely to have had previous
repair of ascending aortic dissection (Table 1). There were
trends toward fewer recent cerebrovascular accidents and
fewer previous cardiovascular operations in the AVS group.
Severe aortic regurgitation was more common in the AVR
group (9/45, 20%) than in the AVS group (5/99, 5%;
P ¼ .005). Preoperative New York Heart Association class,
aortic root size, left ventricular ejection fraction, and smok-
ing history were not significantly different between the two
groups.
Questionnaire data were obtained from operating sur-
geons (on the timing of their decision between AVR and
AVS techniques and the reasons for their choice) for all pa-
tients in the AVR group and for 101 (96%) patients in the
AVS group. The final decision whether to perform an AVR
or AVS procedure was made intraoperatively for 65 (43%)
of the patients. For 32 patients (21% overall and 70% of
the AVR group), AVR was considered the only option be-
cause the condition of the aortic valve or root was deemed
unsuitable for an AVS procedure. Twelve (26%) of the
AVR patients could have had an AVS procedure but chose
AVR instead. Three AVR patients were already on a regi-1128 The Journal of Thoracic and Cardiovascular Sumen of warfarin therapy for other reasons. In the AVS
group, 78 (77%) patients chose this type of operation be-
cause they wanted to avoid anticoagulation; 19 of these
patients were women of childbearing age. Seven (7%) pa-
tients followed their surgeon’s preference for AVS surgery.
Sixteen (16%) patients requested AVS, but did not specify
the reason for selecting this procedure.
The AVR group had a significantly higher proportion of
patients who underwent emergent and urgent operations
(Table 3). The AVS group had longer operative times, in-
cluding total duration of surgery, aortic clamp time, and
cardiopulmonary bypass time. Similar proportions of
AVR and AVS patients underwent concomitant surgical
procedures.
Two (4%) of the 30-day valve-related complications oc-
curred in the AVR group, and 3 (3%) occurred in the AVS
group; the difference did not reach statistical significance
(P ¼ .6). Logistic regression analysis did not identify the
type of operative procedure as an independent predictor
of 30-day valve-related complications (P ¼ .5). There
were no significant differences in the rates of cardiac, pul-
monary, and renal complications (Table 4). The total post-
operative ventilatory support time, total time in the
intensive care unit, and length of hospital stay did not differ
significantly between the AVR and AVS groups. At dis-
charge, cardiac rhythm status, New York Heart Association
class, and left ventricular ejection fraction were similar
(Table 5).rgery c May 2009
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DTABLE 4. Early outcomes after aortic root replacement in 151 patients with MFS
Outcomes Total (n ¼ 151) AVR (n ¼ 46) AVS (n ¼ 105) P value
Thirty-day valve-related complications 5 (3%) 2 (4%) 3 (3%) .6*
Structural valvular deterioration 0 0 0 —
Nonstructural dysfunction 3 (2%) 1 (2%) 2 (2%) .5*
Valve thrombosis 0 0 0 —
Embolism 1 (1%) 0 1 (1%) 1.0*
Bleeding 1 (1%) 1 (2%) 0 .3*
Operated valvular endocarditis 0 0 0 —
Mediastinal re-exploration 14 (9%) 6 (13%) 8 (8%) .4*
Cardiac complications 31 (21%) 12 (26%) 19 (18%) .3
Atrial or ventricular arrhythmia requiring
treatment
23 (15%) 9 (20%) 14 (13%) .3
Pericardial effusion requiring drainage 5 (3%) 2 (4%) 3 (3%) .6*
Cardiac failure 4 (3%) 1 (2%) 3 (3%) 1.0*
Pulmonary complications 11 (7%) 6 (13%) 5 (5%) .09*
Total postoperative ventilation support time,
h, median (IQR)
11 (6–19) 12 (6–24) 10 (6–18) .5y
Acute renal dysfunction 1 (1%) 1 (2%) 0 .3*
Multiple organ failure 1 (1%) 1 (2%) 0 .3*
Total time in ICU, h, median (IQR) 36 (24–57) 44 (23–67) 32 (24–51) .5y
Length of hospital stay, d, median (IQR) 7 (5–11) 7 (6–10) 7 (5–11) .8y
Data are presented as number and percentage of patients unless otherwise specified. MFS, Marfan syndrome; AVR, aortic valve-replacing; AVS, aortic valve-sparing; IQR, inter-
quartile range; ICU, intensive care unit. *Fisher’s exact test. yKolmogorov–Smirnov 2-sample test.DISCUSSION
This study is the first international, multicenter effort to
prospectively compare aortic valve operative outcomes in
patients with MFS. The multicenter design is advantageous
for accumulating data on patients with a rare disease because
it allows quicker collection of a sample of adequate size
while avoiding the confounding effects of significant
changes in surgical technique that may occur over time. It
does, of course, make standardization of methods and tech-The Journal of Thoracic and Caniques impossible; however, the variability in surgical tech-
nique in this series parallels that found in general, which
enhances the overall applicability of the results derived
from this investigation.
By design, this registry study does not involve random as-
signment of root replacement techniques. A nonrandomized
approach is appropriate for studies comparing these two pro-
cedures, as suggested by our finding that the final decision
about which technique to use was made intraoperatively inTABLE 5. Cardiac status at the time of discharge
Variable Total (n ¼ 151) AVR (n ¼ 46) AVS (n ¼ 105) P value
Cardiac rhythm
Sinus 144 (95%) 42 (91%) 102 (97%) .2
Atrial fibrillation/flutter 3 (2%) 1 (2%) 2 (2%)
Heart block 2 (1%) 2 (4%) 0
Paced 2 (1%) 1 (2%) 1 (1%)
NYHA class
I 97 (65%) 28 (62%) 69 (66%) .1
II 46 (31%) 13 (29%) 33 (32%)
III 4 (3%) 2 (4%) 2 (2%)
IV 2 (1%) 2 (4%) 0
Left ventricular ejection fraction,%, median (IQR)
(No. of observations)
60 (55–65) 60 (55–65) 60 (55–65) .9y
(135) (40) (95)
Aortic regurgitation (No. of observations) (142) (41) (101)
None/trivial 140 (99%) 40 (98%) 100 (99%) .5*
Mild 2 (1%) 1 (2%) 1 (1%)
Moderate 0 0 0
Severe 0 0 0
Data are presented as number and percentage of patients unless otherwise specified. AVR, aortic valve-replacing; AVS, aortic valve-sparing; NYHA, New York Heart Association;
IQR, interquartile range. *Fisher’s exact test; yKolmogorov–Smirnov 2-sample test.rdiovascular Surgery c Volume 137, Number 5 1129
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Dmore than 40% of cases. A randomized trial would require
extremely narrow anatomic inclusion criteria to minimize
the crossover rate, making it difficult to enroll a sufficient
number of patients in a realistic time frame. Although the
nonrandomized design will make it impossible to determine
whether one method is superior to the other, the data from
this prospective study provide the most accurate comparison
of these surgical techniques to date.
The analysis of early outcomes showed that AVS was per-
formed in 70% of patients with MFS undergoing aortic root
replacement, which is consistent with previously published
results: 73% of 112 consecutive MFS patients in a series
published by Birks and colleagues16 underwent AVS sur-
gery, as well as 58% of 105 patients in a series by de
Oliveira and colleagues17 and 60% of 144 patients in a re-
cently published study by Patel and colleagues.18
Of note, the Yacoub remodeling technique was used in
only 1 of the AVS patients in the current series; this result
reflects the substantial reduction in recent years of surgeons’
enthusiasm for using remodeling techniques in patients with
MFS, at least in these 18 centers. Birks and colleagues16 en-
dorsed the remodeling procedure in a retrospective analysis
of 82 MFS patients in 1999; the results were marred, how-
ever, by relatively high rates of reoperation and aortic regur-
gitation within 5 to 10 years. Since that time, several groups
have expressed concerns that remodeling carries a higher
risk for complications—including operative bleeding, pro-
gressive annular dilatation, and aortic regurgitation—than
does the reimplantation technique.12,14,17,19-23
The absence of early deaths after 151 root replacement op-
erations in this multicenter study is extremely encouraging;
100% early survival—which was also recently reported for
59 MFS patients by Kallenbach and colleagues,24 for 35 pa-
tients by Settepani and colleagues,25 and for 140 patients by
Patel and colleagues18—represents an improvement over
survival rates in earlier series.6,7,16,17 At this stage of the
study, the type of aortic root replacement does not appear
to be a predictor of early valve-related complications. We
recognize, however, that no long-term inferences should
be drawn from these preliminary results and that further fol-
low-up data accumulation and analysis are necessary.
The limitations of this registry study include the inherent
drawbacks of its nonrandomized design, such as the poten-
tial for confounding by clinical indication bias, the inability
to adjust for unknown confounding factors, and the differ-
ence in the sizes of the comparison groups; the latter was
not anticipated at the beginning of the study and may incur
power limitations. Additionally, retrieval and core labora-
tory analysis of all original echocardiographic images have
been particularly challenging. European sites do not
routinely perform postoperative echocardiograms for AVR
patients, and, in several instances, the images from interna-
tional sites had image formatting compatibility issues. Fi-
nally, it is important to recognize that this study was not1130 The Journal of Thoracic and Cardiovascular Sintended to evaluate differences in long-term durability,
which is certainly an end point of major clinical importance;
at least 10 years of follow-up would be required to address
this issue.
To summarize, the analysis of early outcomes revealed
that AVS was more common than AVR in MFS patients
undergoing root replacement at the participating centers.
Although AVS procedures required longer aortic clamp
and cardiopulmonary bypass times, the added complexity
of AVS root replacement did not translate into adverse early
outcomes. Subsequent analyses will compare the 3-year
durability of these two approaches.
Stephen N. Palmer, PhD, ELS, contributed to the editing of this
manuscript.
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Appendix
Study Cores: Institution (Core Director)
Data Coordination Center and Surgical Core: Baylor
College of Medicine (J. S. Coselli, Study Principal Investi-
gator)
Marfan Diagnostic Core: Johns Hopkins Hospital (H.
C. Dietz)
ImagingCore:Mayo Clinic, Rochester (H.M. Connolly)
Genetic Repository: University of Texas Medical
School at Houston (D. M. Milewicz)
Participating Study Sites: Institution (Site Principal
Investigator, Number of Patients Enrolled)
Argentina: Institute of Cardiology and Cardiovascular
Surgery—Favaloro Foundation (R. R. Favaloro, 10 pa-
tients).
Canada:University of OttawaHeart Institute (K-L. Chan,
1 patient).
Germany: Hannover Medical School (A. Haverich, 5 pa-
tients); University Clinic of Schleswig-Holstein (H. H. Si-
evers, 6 patients); University of Leipzig (F. W. Mohr, 14
patients).
Netherlands: Leiden UniversityMedical Center (M. I. M.
Versteegh, 1 patient).
USA: Baylor College of Medicine (J. S. Coselli, 8 pa-
tients); CentralMaine Heart and Vascular Institute (R. P. Co-
chran, C. Frumiento, 1 patient); Johns Hopkins Hospital (V.
L. Gott, L. A. Vricella, 16 patients); Loyola University Med-
ical Center (J. P. Schwartz, 3 patients);Mayo Clinic, Roches-
ter (T. M. Sundt III, 21 patients); Missouri Baptist Medical
Center (N. T. Kouchoukos, 5 patients); Montefiore Medical
Center (A. DeAnda, 2 patients); New York Presbyterian–
Cornell Hospital (L. N. Girardi, 7 patients); Northwestern
University Feinberg School of Medicine (T. G. Gleason, C.
Malaisrie, 2 patients); Stanford University (D. C. Miller, 19
patients); University of Pennsylvania (J. E. Bavaria, 19 pa-
tients); Washington University (M. R. Moon, 11 patients).
Discussion
Dr Alan D. Hilgenberg (Boston, Mass). Dr Coselli, congratula-
tions to you and your colleagues for designing and implementing this
very important study. The presentation is a report of the current prac-
tice of aortic root repair in patients withMFS from centers in EuropeThe Journal of Thoracic and Ca23. Svensson LG, Deglurkar I, Ung J, Pettersson G, Gillinov AM,
D’Agostino RS, et al. Aortic valve repair and root preservation by remodel-
ing, reimplantation, and tailoring: technical aspects and early outcome. J
Card Surg. 2007;22:473-9.
24. Kallenbach K, Baraki H, Khaladj N, Kamiya H, Hagl C, Haverich A, et al. Aortic
valve-sparing operation in Marfan syndrome: what do we know after a decade?
Ann Thorac Surg. 2007;83:S764-8.
25. Settepani F, Szeto WY, Pacini D, De Paulis R, Chiariello L, Di Bartolomeo R,
et al. Reimplantation valve-sparing aortic root replacement in Marfan syndrome
using the Valsalva conduit: an intercontinental multicenter study. Ann Thorac
Surg. 2007;83:S769-73.
and North and South America. First of all, it is remarkable that there
was no 30–day mortality in 151 patients, attesting to the safety of
these complex surgical procedures. Seventy percent of the operations
were valve-sparing, all but two of them were of the reimplantation
type, and about two thirds included repair with sinuses.
The patients undergoing AVR were different from those under-
going AVS in several important characteristics. They were older,
they had more preoperative aortic regurgitation, and they under-
went more nonelective operations. These factors probably will af-
fect the long–term results in addition to the presence of
a mechanical valve when comparisons with the outcomes of
AVS patients are made.
The most important information from this study will come from
the years of follow-up data that we hope you will accumulate. The
late results of composite valve graft replacement in patients with
MFS have been reported at least a couple of times in the last sev-
eral years. Survival at 10 years of 75% was reported by Gott in the
New England Journal of Medicine study in 1999. More recent data
from Hopkins presented at the Society of Thoracic Surgeons meet-
ing in 2008 by Cameron had an 85% survival at 10 years. Al-
though these results are good, I suspect that the late results in
terms of survival and freedom from thromboembolism in the
AVS group will be even better in this study. However, how dura-
ble will the AVS operations be in terms of avoiding late operation
for aortic regurgitation? David and Feindel reported freedom from
moderate or severe aortic insufficiency in reimplantation proce-
dures to be 94% at 10 years, and in their studies, MFS was not
a risk factor for late aortic insufficiency. This study should be
able to show whether other surgeons throughout the world can
achieve similar results. I hope that you will keep gathering this im-
portant follow-up data.
I have a couple of questions. Have the participating centers
agreed to include their entire experience with consecutive MFS
patients, and if not, do you think this will make a difference in
the outcomes?
Dr Coselli. They have agreed, and I do believe that not enrolling
consecutive patients would affect the results. The intent has been
that once investigators agreed to participate in the study, they
would recruit and screen consecutive patients. I believe that, so
far, compliance has been very good and consecutive patients
have been screened.
Dr Hilgenberg. I think that would be important. I am assuming
that AVS repair is the preferred operation in all of the centers. What
are the common reasons that valves were replaced, if you know,
and were there situations in which valves might have been spared
if the patient had been referred earlier for surgery?rdiovascular Surgery c Volume 137, Number 5 1131
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decision as to which operation to perform was ultimately made at
the time of surgery; the decision to replace the valve was made
by the surgeon, and it primarily revolved around anatomic features
that the surgeons, who are all well-versed in valve-sparing tech-
niques, believed would compromise the durability of a valve-spar-
ing repair.
There were also some patients whose primary concern was that
they did not want to have a second procedure and did not want to
subject themselves to the risks of the potential lack of durability
of the procedure; these patients selected having a mechanical valve
at the outset.
Dr Hilgenberg. David and Feindel perform cusp repair fre-
quently in these operations, and I think it would be of interest to
the audience to know whether cusp repair was used often or rarely
in this series of patients.
Dr Coselli. In this series of patients, relatively rarely; only 17%
of the patients had cusp repair.
Dr Hilgenberg. One final comment: I am sitting here with my
colleague, Cary Akins, who formulates the reporting of valve-re-
lated complications, and I think the re-exploration for bleeding in
this series really does not belong in the valve-related complications.
That is a surgical complication, not necessarily valve-related, I
believe.
Dr Tirone E. David (Toronto, Ontario, Canada). I am sorry
that I am not participating in this study. I think it is important to
have information regarding the aortic cusps in this database. In1132 The Journal of Thoracic and Cardiovascular Sumy experience with AVS procedures during the past 19 years,
what determines whether a valve can be spared or not is the quality
of the aortic cusps. In at least half of my patients with MFS, I had to
repair the cusps to spare the valve. In other words, these patients
had premature cusp degeneration just as in mitral valve prolapse.
Unless you do something with the cusps, I am surprised that you
ended up with no aortic insufficiency. Do you have data on how
many cusps were abnormal?
Dr Coselli. In the way you describe it, no.
Dr David. I propose that you add this to the database. We find it
the single most important determinant of feasibility of repairing
these valves. Cusps with large stress fenestrations, overstretched
and thinned out, should not be preserved, and AVR probably re-
sults in better outcomes.
Dr Coselli. Dr David, thank you for your comments and thank
you for your immense contribution and pioneering work in this
area. All of the centers that participated involved surgeons who
are well-versed in the techniques and carry on a practice that allows
them to very reliably carry out AVS procedures; I believe that the
results, with no deaths, no strokes, and no moderate or severe aortic
valve regurgitation in the early postoperative period, confirm their
levels of expertise. I think it would be challenging for this type of
registry—which already collects an immense amount of data from
very diverse institutions across the globe—to accumulate the kind
of detailed information on the leaflets that a single surgeon and
a single center can. But I appreciate the insight, and ideally we
can incorporate that.rgery c May 2009
